<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Opportunities center on unmet need, gene and RNA therapies, precision biologics, AI-enabled discovery and diagnosis, real-world evidence, and expansion into underserved regions.Dublin, Sept. 14, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- <a href="https://www.researchandmarkets.com/report/orphan-drug?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=35hbvz&amp;utm_campaign=2349769+-+Orphan+Drugs+Market+-+Global+Forecast+2026-2032+Now+Available%2c+Analyzes+Biologics%2c+Gene+Therapy%2c+Small+Molecules%2c+and+Tissue+Therapy&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Orphan Drugs Market - Global Forecast 2026-2032">"Orphan Drugs Market - Global Forecast 2026-2032"</a> has been added to ResearchAndMarkets.com's offering. The orphan drugs market research report examines a sector projected to reach USD 213.45 billion in 2026 and grow at a CAGR of 11.96% to USD 421.32 billion by 2032. It assesses the scientific, regulatory, commercial, and geographic forces shaping treatments for rare diseases, which affect an estimated 300 million people worldwide. With approximately 95% of more than 7,000 identified rare diseases still lacking an approved treatment, the market presents substantial opportunities for targeted innovation. Market Growth and Policy Drivers Growth is supported by regulatory incentives, accelerated pathways, advances in biomarker science, and rising collaboration among biopharmaceutical companies, healthcare systems, and patient organizations. Key frameworks include the U.S. Orphan Drug Act for conditions affecting fewer than 200,000 people and the European Union pathway for serious diseases affecting no more than 5 in 10,000 people. The analysis provides decision-makers with a practical basis for evaluating development priorities, market entry options, and policy-related risks across rare disease portfolios. Transformative Market Shifts The market is moving beyond traditional small molecules and enzyme replacement therapies toward precision biologics, gene therapies, RNA-based medicines, and cell-based interventions. Genomics, newborn screening, natural history studies, and real-world evidence are improving diagnosis, patient identification, and clinical endpoint selection. Payers increasingly require durability data, outcomes-based evidence, and transparent value justification for high-cost or one-time treatments. Patient advocacy organizations are also becoming essential partners in registries, trial recruitment, endpoint development, and post-approval monitoring. Artificial Intelligence Applications Artificial intelligence is supporting target identification, phenotype matching, literature analysis, protein modeling, and drug repurposing. AI-enabled tools can connect fragmented genomic, clinical, imaging, and registry datasets to uncover disease mechanisms and identify suitable patients. Machine learning also contributes to patient stratification, site selection, synthetic control arms, pharmacovigilance, and real-world evidence analysis. These insights can strengthen portfolio prioritization and create a competitive advantage, although privacy, bias, interoperability, explainability, and regulatory validation remain important risks. Regional Market Insights . North America: The United States leads commercialization through FDA incentives, biomedical investment, clinical trial networks, and patient advocacy. Canada combines national policy initiatives with provincial reimbursement mechanisms. . Europe: The European Medicines Agency, advanced health technology assessment systems, and specialist networks support development. Pricing and reimbursement differences across the United Kingdom, Germany, France, Italy, and Spain can produce access variability. . Asia-Pacific: Japan, China, South Korea, Australia, and India are expanding rare disease policies, genetic testing, clinical research, and expedited review pathways. . Latin America, Middle East, and Africa: Brazil, Mexico, GCC countries, and selected African markets offer long-term potential, but diagnostic capacity, affordability, reimbursement, and specialist access remain uneven. Economic and Country Group Insights ASEAN countries are developing genomic medicine, screening programs, and cross-border research capabilities. GCC markets are investing in national genome initiatives and specialty hospitals. The European Union remains a benchmark for coordinated regulation, while BRICS countries offer large patient populations and expanding trial potential. G7 countries continue to influence global evidence, pricing, and regulatory standards. Many NATO countries also maintain biomedical systems that support rare disease research and resilient pharmaceutical supply chains. Country-level comparisons enable organizations to identify attractive launch markets while accounting for local reimbursement, procurement, and access constraints. Strategic Priorities for Industry Leaders . Establish natural history studies, patient registries, validated biomarkers, patient-reported outcomes, and real-world evidence plans before pivotal trials. . Partner with advocacy groups, reduce trial burden, expand genetic testing, and align endpoints with patient and caregiver priorities. . Prepare scalable manufacturing, cold-chain logistics, pharmacovigilance, and long-term follow-up systems for advanced therapies. . Evaluate value-based agreements, managed entry models, early access programs, and country-specific reimbursement evidence. . Apply AI through validated, explainable use cases supported by strong data governance and bias controls. Key Takeaways from This Report . The market is forecast to grow from USD 213.45 billion in 2026 to USD 421.32 billion by 2032. . Large unmet treatment needs continue to support investment in rare disease innovation. . Gene therapies, RNA medicines, precision biologics, and AI are reshaping discovery and development. . Early evidence planning, patient engagement, manufacturing readiness, and market access strategy are critical to commercial success. . Regional opportunities vary considerably based on regulation, reimbursement, diagnostics, and healthcare infrastructure. Key Attributes: <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Report Attribute</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">Details</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">No. of Pages</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">189</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecast Period</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">2026 - 2032</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Estimated Market Value (USD) in 2026</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$213.45 Billion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecasted Market Value (USD) by 2032</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$421.32 Billion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Compound Annual Growth Rate</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">11.9%</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">Regions Covered</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">Global</td></tr></table> Key Topics Covered: 1. Preface 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Segmentation &amp; Coverage 1.4. Years Considered for the Study 1.5. Currency Considered for the Study 1.6. Language Considered for the Study 1.7. Key Stakeholders 2. Research Methodology 2.1. Introduction 2.2. Research Design 2.2.1. Primary Research 2.2.2. Secondary Research 2.3. Research Framework 2.3.1. Qualitative Analysis 2.3.2. Quantitative Analysis 2.4. Market Size Estimation 2.4.1. Top-Down Approach 2.4.2. Bottom-Up Approach 2.5. Data Triangulation 2.6. Research Outcomes 2.7. Research Assumptions 2.8. Research Limitations 3. Executive Summary 3.1. Introduction 3.2. CXO Perspective 3.3. New Revenue Opportunities 3.4. Next-Generation Business Models 3.5. Industry Roadmap 4. Market Overview 4.1. Introduction 4.2. Industry Ecosystem &amp; Value Chain Analysis 4.2.1. Supply-Side Analysis 4.2.2. Demand-Side Analysis 4.2.3. Stakeholder Analysis 4.3. Market Dynamics 4.3.1. Key Drivers 4.3.2. Key Restraints 4.3.3. Key Opportunities 4.3.4. Key Challenges 4.4. Porter's Five Forces Analysis 4.5. PESTLE Analysis 4.6. Market Outlook 4.6.1. Near-Term Market Outlook (0-2 Years) 4.6.2. Medium-Term Market Outlook (3-5 Years) 4.6.3. Long-Term Market Outlook (5-10 Years) 4.7. Go-to-Market Strategy 5. Market Insights 5.1. Consumer Insights &amp; End-User Perspective 5.2. Consumer Experience Benchmarking 5.3. Opportunity Mapping 5.4. Distribution Channel Analysis 5.5. Pricing Trend Analysis 5.6. Regulatory Compliance &amp; Standards Framework 5.7. ESG &amp; Sustainability Analysis 5.8. Disruption &amp; Risk Scenarios 5.9. Return on Investment &amp; Cost-Benefit Analysis 6. Cumulative Impact of Artificial Intelligence 2026 7. Orphan Drugs Market, by Therapeutic Area 7.1. Introduction 7.2. Immunology 7.3. Infectious Diseases 7.4. Metabolic Disorders 7.5. Neurology 7.6. Oncology 8. Orphan Drugs Market, by Product Type 8.1. Introduction 8.2. Biologics 8.2.1. Enzymes 8.2.2. Monoclonal Antibodies 8.2.3. Recombinant Proteins 8.3. Gene Therapy 8.3.1. Non-Viral Vector 8.3.2. Viral Vector 8.4. Small-Molecule 8.5. Tissue Therapy 9. Orphan Drugs Market, by Administration Route 9.1. Introduction 9.2. Inhalation 9.3. Injectable 9.3.1. Intramuscular 9.3.2. Intravenous 9.3.3. Subcutaneous 9.4. Oral 9.5. Topical 10. Orphan Drugs Market, by Patient Type 10.1. Introduction 10.2. Adult 10.3. Pediatric 10.4. Geriatric 11. Orphan Drugs Market, by Payer Type 11.1. Introduction 11.2. Government Programs 11.3. Out-Of-Pocket 11.4. Private Insurance 12. Orphan Drugs Market, by Distribution Channel 12.1. Introduction 12.2. Offline 12.3. Online 13. Orphan Drugs Market, by End User 13.1. Introduction 13.2. Hospitals 13.3. Specialty Clinics 13.4. Research Institutes 13.5. Homecare Settings 14. Orphan Drugs Market, by Region 14.1. Introduction 14.2. Asia-Pacific 14.3. Europe 14.4. North America 14.5. Latin America 14.6. Africa 14.7. Middle East 15. Orphan Drugs Market, by Group 15.1. Introduction 15.2. NATO 15.3. G7 15.4. European Union 15.5. BRICS 15.6. ASEAN 15.7. GCC 16. Orphan Drugs Market, by Country 16.1. Introduction 16.2. United States 16.3. China 16.4. Germany 16.5. Japan 16.6. India 16.7. United Kingdom 16.8. France 16.9. Canada 16.10. Italy 16.11. Australia 16.12. South Korea 16.13. Brazil 16.14. Mexico 16.15. Russia 16.16. Spain 17. Competitive Landscape 17.1. Market Share Analysis, 2025 17.2. Market Concentration Analysis, 2025 17.2.1. Concentration Ratio (CR) 17.2.2. Herfindahl Hirschman Index (HHI) 17.3. Recent Developments &amp; Impact Analysis, 2025 17.4. Product Portfolio Analysis, 2025 17.5. Benchmarking Analysis, 2025 18. Company Profiles 18.1. AbbVie Inc 18.2. Alexion Pharmaceuticals Inc 18.3. Alnylam Pharmaceuticals Inc 18.4. Amgen Inc 18.5. Astellas Pharma Inc 18.6. AstraZeneca PLC 18.7. Bayer AG 18.8. BioMarin Pharmaceutical Inc 18.9. Bristol-Myers Squibb Company 18.10. Daiichi Sankyo Co Ltd 18.11. F. Hoffmann-La Roche Ltd 18.12. FGK Clinical Research GmbH 18.13. Gilead Sciences Inc 18.14. GlaxoSmithKline PLC 18.15. Incyte Corporation 18.16. Ipsen Pharma 18.17. Johnson &amp; Johnson Services Inc 18.18. Kyowa Kirin Co Ltd 18.19. Novartis AG 18.20. Novo Nordisk AS 18.21. Pfizer Inc 18.22. Recordati SpA 18.23. Regeneron Pharmaceuticals Inc 18.24. Sanofi SA 18.25. Sarepta Therapeutics Inc 18.26. Swedish Orphan Biovitrum AB 18.27. Takeda Pharmaceutical Company Limited 18.28. UCB SA 18.29. Ultragenyx Pharmaceutical Inc 18.30. Vertex Pharmaceuticals Incorporated 19. Key Experts For more information about this report visit <a href="https://www.researchandmarkets.com/report/orphan-drug?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=35hbvz&amp;utm_campaign=2349769+-+Orphan+Drugs+Market+-+Global+Forecast+2026-2032+Now+Available%2c+Analyzes+Biologics%2c+Gene+Therapy%2c+Small+Molecules%2c+and+Tissue+Therapy&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/5tjv1f</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/ZDcyZmVmNWItYzI1YS00YzE2LWFlZTYtNjFiZmYwZjc3Nzg4LTEwMjY3MzctMjAyNi0wOS0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

Orphan Drugs Market - Global Forecast 2026-2032 Now Available, Analyzes Biologics, Gene Therapy, Small Molecules, and Tissue Therapy

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn